KBC Securities - Hyloris Pharmaceuticals (HYL) Morning Notes : HYL BB

Report

KBC Securities

Hilde Van Boxstael ...

Mathijs Geerts Danau
Wim Lewi

Morning Notes : HYL BB

: HYL BB

30/12/2025 1 EN

Underlying

Hyloris Pharmaceuticals

See profile

BE0974363955 Euronext Brussels Belgium

Provider

KBC Securities

We are a financial services provider for several types of professional clients, each with distinct needs.

See profile

Analysts

Hilde Van Boxstael

Mathijs Geerts Danau

Wim Lewi

Other Reports on these Companies

KBC Securities

Hyloris FY25 results hold no major surprises

Hyloris reported FY25 results with a cash position of € 13.8m (YE24: € 23.6m), and revenue of € 7.2m (FY24: € 8.5m), driven by increased royalties but offset by lower milestone payments. Hyloris is yet to receive income related to commercialisation of Maxigesic IV in the US as the launch has been paused and restarted. The company did not provide specific cash runway guidance, but believes it has funding for development and strategic growth. € 6 TP and Hold maintained.

5h / 10m 5h / 10m 1 EN

KBC Securities

Morning Notes : COMB BB, HYL BB, TESB BB, UCB BB

: COMB BB, HYL BB, TESB BB, UCB BB

5h / 23m 5h / 23m 1 EN

KBC Securities

Morning Notes : ABI BB, AGN NA, ARCAD NA, BESI NA, ENX FP, GIMB BB, HYL BB, IBAB BB, KIN BB, MTLS US, VGP BB, AZE BB, ZEAL DC

: ABI BB, AGN NA, ARCAD NA, BESI NA, ENX FP, GIMB BB, HYL BB, IBAB BB, KIN BB, MTLS US, VGP BB, AZE BB, ZEAL DC

February 19, 2026 February 19, 2026 1 EN

Hyloris FY25 results hold no major surprises

5h / 10m 5h / 10m 1 EN

Wim Hoste

Wim Hoste

Tessenderlo FIRST LOOK: FY25 EBITDA and FY26 guidance slight miss

Tessenderlo's FY25 adjusted EBITDA increased by 8.5% to 288.1m, which was 3% below our forecast and 6% below consensus. FY26 guidance calls for adjusted EBITDA in line with 2025 which is also below our and consensus forecasts. Despite the difficult macro economic environment, we remind that the company is using its solid balance sheet and FCF to regularly buy back own shares. We consider valuation to be attractive enough from maintaining our Accumulate rating with target price maintained at € 28.

5h / 14m 5h / 14m 1 EN

Hilde Van Boxstael ... (+6)

Hilde Van Boxstael
Jacob Mekhael
Livio Luyten
Mathijs Geerts Danau
Thomas Couvreur
Wim Hoste

Morning Notes : COMB BB, HYL BB, TESB BB, UCB BB

: COMB BB, HYL BB, TESB BB, UCB BB

5h / 23m 5h / 23m 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

Morning Notes : HYL BB

We are a financial services provider for several types of professional clients, each with distinct needs.

Hyloris FY25 results hold no major surprises

Morning Notes : COMB BB, HYL BB, TESB BB, UCB BB

Morning Notes : ABI BB, AGN NA, ARCAD NA, BESI NA, ENX FP, GIMB BB, HYL BB, IBAB BB, KIN BB, MTLS US, VGP BB, AZE BB, ZEAL DC

Hyloris FY25 results hold no major surprises

Tessenderlo FIRST LOOK: FY25 EBITDA and FY26 guidance slight miss

Morning Notes : COMB BB, HYL BB, TESB BB, UCB BB

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe